References
- Lai MW, Klein-Schwartz W, Rodgers GC, Abrams JY, Haber DA, Bronstein AC, Wruk KM. 2005 annual report of the American Association of Poison Control Centers’ national poisoning and exposure database. Clinical Toxicology 2006; 44(6–7)803–932
- Makar AB, Tephly TR. Inhibition of monkey liver alcohol dehydrogenase by 4-methylpyrazole. Biochem Med. Aug, 1975; 13(4)334–42
- McMartin KE, Makar AB, Martin G, Palese M, Tephly TR. Methanol poisoning. I. The role of formic acid in the development of metabolic acidosis in the monkey and the reversal by 4-methylpyrazole. Biochem Med 1975; 13(4)319–33
- Pietruszko R. Mammalian liver alcohol dehydrogenases. [review] [148 refs]. Adv Exp Med Biol 1975; 56: 1–31
- Brent J, McMartin K, Phillips S, Aaron C, Kulig K. Methylpyrazole for Toxic Alcohols Study Group. Fomepizole for the treatment of methanol poisoning. N Engl J Med 2001; 344(6)424–9
- Brent J, McMartin K, Phillips S, Burkhart KK, Donovan JW, Wells M, Kulig K. Fomepizole for the treatment of ethylene glycol poisoning. methylpyrazole for toxic alcohols study group [see comment]. N Engl J Med 1999; 340(11)832–8
- Li TK, Theorell H. Human liver alcohol dehydrogenase: Inhibition by pyrazole and pyrazole analogs. Acta Chem Scand 1969; 23(3)892–902
- Jacobsen D, Sebastian CS, Blomstrand R, McMartin KE. 4-methylpyrazole: A controlled study of safety in healthy human subjects after single, ascending doses. Alcohol Clin Exp Res 1988; 12(4)516–22
- McMartin KE, Hedstrom KG, Tolf BR, Ostling-Wintzell H, Blomstrand R. Studies on the metabolic interactions between 4-methylpyrazole and methanol using the monkey as an animal model. Arch Biochem Biophys 1980; 199(2)606–14
- Jacobsen D, Barron SK, Sebastian CS, Blomstrand R, McMartin KE. Non-linear kinetics of 4-methylpyrazole in healthy human subjects. Eur J Clin Pharmacol 1989; 37(6)599–604
- McMartin KE, Brent J, META Study Group. Pharmacokinetics of fomepizole (4MP) in patients. J Toxicology Clinical Toxicology 1998; 36(5)450–1
- Pietruszko R. Human liver alcohol dehydrogenase—inhibition of methanol activity by pyrazole, 4-methylpyrazole, 4-hydroxymethylpyrazole and 4-carboxypyrazole. Biochem Pharmacol 1975; 24(17)1603–7
- McMartin KE, Collins TD. Distribution of oral 4-methylpyrazole in the rat: Inhibition of elimination by ethanol. J Toxicol Clin Toxicol 1988; 26(7)451–66
- Wallemacq PE, Vanbinst R, Haufroid V, Di Fazio V, Konig J, Detaille T, Hantson P. Plasma and tissue determination of 4-methylpyrazole for pharmacokinetic analysis in acute adult and pediatric methanol/ethylene glycol poisoning. Ther Drug Monit 2004; 26(3)258–62
- Jacobsen D, Sebastian CS, Dies DF, Breau RL, Spann EG, Barron SK, McMartin KE. Kinetic interactions between 4-methylpyrazole and ethanol in healthy humans. Alcohol Clin Exp Res 1996; 20(5)804–9
- D'Argenio DZ, Schumitzky A. ADAPT II user's guide: Pharmacokinetic/pharmacodynamic systems analysis software, biomedical simulations resource, USC. Los Angeles, CA, USA 1997
- Mayersohn M, Owens SM, Anaya AL, Bliss M, Achari R. 4-methylpyrazole disposition in the dog: Evidence for saturable elimination. J Pharm Sci 1985; 74(8)895–6
- Jacobsen D, Sebastian CS, Barron SK, Carriere EW, McMartin KE. Effects of 4-methylpyrazole, methanol/ethylene glycol antidote, in healthy humans. J Emerg Med 1990; 8(4)455–61
- Baud FJ, Bismuth C, Garnier R, Galliot M, Astier A, Maistre G, Saffer M. 4-methylpyrazole may be an alternative to ethanol therapy for ethylene glycol intoxication in man. J Toxicol Clin Toxicol 1986–87; 24(6)463–83, 87
- Hantson P, Wallemacq P, Brau M, Vanbinst R, Haufroid V, Mahieu P. Two cases of acute methanol poisoning partially treated by oral 4-methylpyrazole. Intensive Care Med 1999; 25(5)528–31
- Feierman DE, Cederbaum AI. Inhibition of microsomal oxidation of ethanol by pyrazole and 4-methylpyrazole in vitro. Biochemical J 1986; 239: 671–7